Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients-Reference-Cited by-同舟云学术

Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients

Published:2016-03-02 Issue:6 Volume:32 Page:991-996
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Diaby Vakaramoko¹,Ali Askal A.¹,Adunlin Georges²,Kohn Christine G.³,Montero Alberto J.⁴

Affiliation:

1. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA;

2. Virginia Commonwealth University School of Medicine, Richmond, VA, USA;

3. University of Saint Joseph School of Pharmacy, Hartford Hospital Evidence-based Practice Center, Hartford, CT, USA;

4. Cleveland Clinic, Taussig Cancer Institute, Department of Solid Tumor Oncology, Cleveland, OH, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2016.1149056

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2024-02-28

2. Cost-effectiveness of Trastuzumab emtansine and Capecitabine plus lapatinib in adjuvant treatment of Human Epidermal Growth Factor Receptor 2– Positive Metastatic Breast Cancer in China;2024-02-27

3. Cost-effectiveness of Metronomic chemotherapy vs Weekly Intravenous Paclitaxel in patients with ER+/HER2-Metastatic Breast Cancer;2024-01-23

4. Drugs influencing on PCSK9 activity: modelling of efficacy in patients who had myocardial infarction with uncontrolled dyslipidemia;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2023-07-31

5. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer;The Breast;2022-10